These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 38317053)
1. Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis. Covert LT; Prinz JA; Swain-Lenz D; Dvergsten J; Truskey GA Rheumatology (Oxford); 2024 Sep; 63(SI2):SI240-SI248. PubMed ID: 38317053 [TBL] [Abstract][Full Text] [Related]
2. Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis. Covert LT; Patel H; Osman A; Duncan L; Dvergsten J; Truskey GA Rheumatology (Oxford); 2024 Jan; 63(1):209-217. PubMed ID: 37094222 [TBL] [Abstract][Full Text] [Related]
3. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769 [TBL] [Abstract][Full Text] [Related]
4. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature. Sener S; Cam V; Ozen S; Batu ED Semin Arthritis Rheum; 2024 Jun; 66():152426. PubMed ID: 38442462 [TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study. Solignac M; Cabrera N; Fouillet-Desjonqueres M; Duquesne A; Laurent A; Foray AP; Viel S; Zekre F; Belot A J Autoimmun; 2024 Jul; 147():103248. PubMed ID: 38797048 [TBL] [Abstract][Full Text] [Related]
6. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Fitton J; Melville AR; Emery P; Nam JL; Buch MH Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938 [TBL] [Abstract][Full Text] [Related]
8. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356 [TBL] [Abstract][Full Text] [Related]
9. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130 [TBL] [Abstract][Full Text] [Related]
10. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Yu Z; Wang L; Quan M; Zhang T; Song H Rheumatology (Oxford); 2021 Apr; 60(4):1700-1707. PubMed ID: 33024992 [TBL] [Abstract][Full Text] [Related]
11. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556 [TBL] [Abstract][Full Text] [Related]
12. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib. Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292 [TBL] [Abstract][Full Text] [Related]
13. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells. Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713 [TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202 [TBL] [Abstract][Full Text] [Related]
15. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells. Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240 [TBL] [Abstract][Full Text] [Related]
18. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Ll Wilkinson MG; Deakin CT; Papadopoulou C; Eleftheriou D; Wedderburn LR Pediatr Rheumatol Online J; 2021 Sep; 19(1):146. PubMed ID: 34563217 [TBL] [Abstract][Full Text] [Related]
19. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease. Harada H; Shoda H; Tsuchiya H; Misaki M; Sawada T; Fujio K Rheumatol Int; 2024 May; 44(5):961-971. PubMed ID: 38456909 [TBL] [Abstract][Full Text] [Related]
20. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience. Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]